Articles for category: Most Popular

Russ Cohen

Most Popular

Unleashing the Potential of Leading Stocks for Long-Term Gains Unleashing the Potential of Leading Stocks for Long-Term Gains

The “Magnificent Seven” stocks — Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta Platforms, and Tesla — have notably outperformed the stock market over the last five years. For instance, considering the median performer among this group, Microsoft, boasts a compound annual growth rate (CAGR) of 26% during this period. This figure nearly doubles the return offered ...

Russ Cohen

Most Popular

Unleashing the Power of $200 for Millionaire Status Unleashing the Power of $200 for Millionaire Status

A modest $200 contribution per month can lay the foundation for immense wealth accumulation over one’s career. Utilizing a strategy known as dollar-cost averaging in the stock market not only eliminates fret over market fluctuations but also fosters a fruitful financial journey. It’s imperative to grasp that market downturns are inevitable, but the economy’s long-term ...

Russ Cohen

Most Popular

Investors React to Toyota’s 13.6% Decline Post Q1 Earnings & Sales Beat Investors React to Toyota’s 13.6% Decline Post Q1 Earnings & Sales Beat

Toyota’s stock has taken a nosedive, dropping 13.6% since the company unveiled its fiscal first-quarter 2025 financial results on August 1. Despite exceeding the Zacks Consensus Estimate by reporting earnings of $6.35 per share, the figure was a step down from the $7.05 per share earned in the same quarter the previous year. Consolidated revenues ...

Russ Cohen

Most Popular

Uncovering Hidden Gems: Undervalued Stocks Worth A Second Look

While it may seem safer to bet on established companies, the thrill of discovering undervalued stocks that Wall Street is neglecting can be enticing. However, this approach is not without risk. These overlooked stocks may have strong fundamentals, but changing economic conditions can cloud their future prospects. Playing it safe rarely leads to exceptional returns. ...

Russ Cohen

Most Popular

Outset Medical, Inc. Investigation: Financial Woes and Investor Fallout Outset Medical, Inc. Investigation: Financial Woes and Investor Fallout

Glancy Prongay & Murray LLP (“GPM”), a renowned legal heavyweight in the realm of securities fraud, continues to scrutinize Outset Medical, Inc. (“Outset Medical” or the “Company”), eliciting curiosity and concern among investors embroiled in the unfolding saga. The Financial Fiasco On August 7, 2024, Outset Medical disclosed its second-quarter financial figures for the fiscal ...

Russ Cohen

Most Popular

Nasdaq’s Stricter Delisting Process Impact on Direxion Small Cap Bull And Bear 3X ETFs The Unveiling of Nasdaq’s Proposed Enhanced Delisting Criteria:

Nasdaq’s NDAQ recent move to tighten its delisting procedures for non-compliant companies has set off reverberations in the financial world. The focus is on penny stocks that fail to maintain a minimum bid price above $1 for 30 consecutive sessions, leading to a potential swift exit from the exchange if remedial action is not taken ...

Russ Cohen

Most Popular

United States Antimony Quarterly Earnings Update

Source: iQoncept / Shutterstock United States Antimony (NYSEMKT:UAMY) has recently disclosed its financial performance for the second quarter of 2024. The company has not reported any Earnings Per Share (EPS) figures for the quarter. However, the company has announced revenue of $2.81 million for the period.

Russ Cohen

Most Popular

Comparing TSLA and RIVN: A Deep Dive into the EV Stock Duel

Tesla vs. Rivian: The EV Showdown Upon analyzing two prominent EV stocks – Tesla (TSLA) and Rivian Automotive (RIVN) – through TipRanks’ Comparison Tool, divergent patterns emerge. Tesla glimmers with optimism while Rivian garners a more tempered view. Renowned for its innovative vehicle line-up including the Cybertruck, Tesla stands out for its all-electric vehicles, solar ...

Russ Cohen

Most Popular

Piper Sandler’s Defensive Biotech Selection Amid Market Uncertainty Piper Sandler’s Defensive Biotech Selection Amid Market Uncertainty

ryasick As market volatility rattles investor confidence worldwide, Piper Sandler has unveiled a strategic lineup of eight defensive growth stocks within the biopharmaceutical sector. This announcement follows a turbulent period where equities experienced a 3% dip in the S&P 500 on Monday, catalyzed by a lackluster U.S. jobs report. Although the benchmark index displayed signs ...